These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 32597142)

  • 1. A regulatory take on cannabis and cannabinoids for medicinal use in the European Union.
    Lipnik-Štangelj M; Razinger B
    Arh Hig Rada Toksikol; 2020 Mar; 71(1):12-18. PubMed ID: 32597142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mapping regulatory models for medicinal cannabis: a matrix of options.
    Belackova V; Shanahan M; Ritter A
    Aust Health Rev; 2018 Aug; 42(4):403-411. PubMed ID: 28553995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The legal framework governing the quality of (traditional) herbal medicinal products in the European Union.
    Kroes BH
    J Ethnopharmacol; 2014 Dec; 158 Pt B():449-53. PubMed ID: 25086408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.
    Tomić S; Sucić AF; Martinac AI
    Regul Toxicol Pharmacol; 2010; 57(2-3):325-32. PubMed ID: 20385190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical use of cannabis and cannabinoids containing products - Regulations in Europe and North America.
    Abuhasira R; Shbiro L; Landschaft Y
    Eur J Intern Med; 2018 Mar; 49():2-6. PubMed ID: 29329891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality Requirements for Medicinal Cannabis and Respective Products in the European Union - Status Quo.
    Veit M
    Planta Med; 2023 Jul; 89(8):808-823. PubMed ID: 35338476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cannabis and the exocannabinoid and endocannabinoid systems. Their use and controversies.
    Millán-Guerrero RO; Isais-Millán S
    Gac Med Mex; 2019; 155(5):471-474. PubMed ID: 32091020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cannabis and cannabinoid drug development: evaluating botanical versus single molecule approaches.
    Bonn-Miller MO; ElSohly MA; Loflin MJE; Chandra S; Vandrey R
    Int Rev Psychiatry; 2018 Jun; 30(3):277-284. PubMed ID: 30179534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cannabinoids in cancer treatment: Therapeutic potential and legislation.
    Dariš B; Tancer Verboten M; Knez Ž; Ferk P
    Bosn J Basic Med Sci; 2019 Feb; 19(1):14-23. PubMed ID: 30172249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive Review of Medicinal Marijuana, Cannabinoids, and Therapeutic Implications in Medicine and Headache: What a Long Strange Trip It's Been ….
    Baron EP
    Headache; 2015 Jun; 55(6):885-916. PubMed ID: 26015168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The legalization of cannabinoid products and standardizing cannabis-drug development in the United States: a brief report
.
    Marcu J
    Dialogues Clin Neurosci; 2020 Sep; 22(3):289-293. PubMed ID: 33162772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cannabinoids: Medical implications.
    Schrot RJ; Hubbard JR
    Ann Med; 2016; 48(3):128-41. PubMed ID: 26912385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Spice in France: mixed herbs containing synthetic cannabinoids].
    Schlatter J; Chiadmi F; Chariot P
    Ann Biol Clin (Paris); 2012; 70(4):413-22. PubMed ID: 22796613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Key elements of legal environments for medical use of cannabis in different countries.
    Knöss W; van de Velde M; Sandvos C; Cremer-Schaeffer P
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2019 Jul; 62(7):855-860. PubMed ID: 31165903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Source of cannabinoids: what is available, what is used, and where does it come from?
    Specchio N; Pietrafusa N; Cross HJ
    Epileptic Disord; 2020 Jan; 22(S1):1-9. PubMed ID: 31941643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Where is industry getting it wrong? A review of quality concerns raised at Day 120 by the Committee For Medicinal Products for Human Use during European Centralised Marketing Authorisation Submissions for Chemical Entity Medicinal Products.
    Borg JJ; Robert JL; Wade G; Aislaitner G; Pirozynski M; Abadie E; Salmonson T; Vella Bonanno P
    J Pharm Pharm Sci; 2009; 12(2):181-98. PubMed ID: 19732496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cannabis for medicinal use: development of pharmacopoeia monographs as a quality standard].
    Manns D; Norwig J; Reh K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2019 Jul; 62(7):806-810. PubMed ID: 31139840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Review of the development in European Legislation on the harmonisation of the laws for medicinal products].
    Lehmann B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):713-21. PubMed ID: 18584107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Interpretation of the concept of 'medicinal product' in relation to herb- and cannabinoid-based products].
    Zsigmond F
    Orv Hetil; 2014 Nov; 155(48):1902-7. PubMed ID: 25417136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medicinal Cannabis and Synthetic Cannabinoid Use.
    Pichini S; Lo Faro AF; Busardò FP; Giorgetti R
    Medicina (Kaunas); 2020 Sep; 56(9):. PubMed ID: 32906770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.